Cerus Corporation 2014 Form 10-K Summary
Business context and reporting period
Cerus Corporation develops and commercializes the INTERCEPT Blood System, designed to reduce pathogens in donated blood components. The platelet and plasma systems were marketed internationally and received FDA approval in December 2014. The red blood cell system remained in development. This filing covers the fiscal year ended December 31, 2014, including fourth-quarter results.
Financial performance and liquidity
| Metric | 2014 | 2013 | Change |
|---|---|---|---|
| Product revenue | $36.4 million | $39.7 million | Down 8% |
| Gross profit | $15.2 million | $17.1 million | Down 11% |
| Product gross margin | 42% | 43% | Down 1 percentage point |
| Research and development expense | $21.8 million | $15.2 million | Up 44% |
| SG&A expense | $37.7 million | $30.0 million | Up 26% |
| Loss from operations | $(44.5) million | $(28.3) million | Loss increased |
| Net loss | $(38.8) million | $(43.3) million | Loss decreased |
| Basic loss per share | $(0.52) | $(0.64) | Improved |
| Net cash used in operations | $(39.8) million | $(26.7) million | Use increased |
Fourth-quarter product revenue was $9.6 million, gross profit was $3.0 million, and net loss was $20.2 million. Fourth-quarter revenue was revised downward by $0.1 million because collection from a Russian customer was considered at risk; the revision increased reported net loss by $0.2 million.
- Cash and cash equivalents were $22.8 million at year-end; short-term investments were $28.5 million, for combined cash, cash equivalents and short-term investments of $51.3 million.
- Working capital was $45.7 million versus $38.7 million at December 31, 2013.
- Debt principal outstanding was $10.0 million under the Oxford Finance term loan, with a net carrying value of $9.9 million. The facility permits up to $30.0 million in total borrowings, subject to conditions.
- Contractual obligations totaled $25.7 million, including $10.8 million of minimum purchase commitments, $12.7 million of debt principal and interest, and $1.2 million of operating leases.
- Financing activities provided $36.5 million, including $18.5 million from equity sales, $11.6 million from exercise of equity incentives and warrants, and $9.8 million from debt proceeds.
Material changes versus the prior comparable period
- Revenue declined primarily because of lower disposable platelet and plasma kit volumes, distributor performance issues, territory transitions and unfavorable euro-to-dollar currency movements. Average selling prices increased and illuminator sales improved, partially offsetting the decline.
- Operating expenses rose substantially as Cerus advanced the red blood cell program, pursued FDA approvals, conducted IDE studies and prepared for the U.S. commercial launch.
- Non-operating results improved because Cerus recorded a $7.7 million non-cash gain from warrant revaluation in 2014 versus a $15.1 million loss in 2013. The 2009 warrants were fully exercised in August 2014; 3.3 million 2010 warrants remained outstanding at year-end.
- Cash used in operations increased by $13.1 million, reflecting higher research, development, commercialization and inventory spending.
- Cerus sold approximately 4.3 million shares under its Cantor at-the-market facility for $18.6 million of net proceeds, compared with approximately 5.4 million shares and $23.5 million in 2013.
- The company received FDA approvals for its platelet and plasma systems in December 2014, a significant regulatory milestone, but meaningful U.S. commercial revenue had not yet begun.
Guidance, outlook, commentary and risks
- Management expected no meaningful U.S. revenue from platelet and plasma sales in 2015 because blood centers needed process validations and site-specific FDA licenses before broader adoption.
- Management expected research and development spending to continue increasing for the chronic-anemia red blood cell trial, U.S. label expansions, additional product configurations, illuminator development and regulatory work. SG&A was also expected to increase as U.S. commercial capabilities were built.
- The European Phase III acute-anemia red blood cell trial and the U.S. Phase II recovery and lifespan study met their primary endpoints. Cerus planned a European CE mark submission for the red blood cell system in the second half of 2016, subject to further development, manufacturing and regulatory requirements.
- The platelet system required a post-approval hemovigilance study. Additional U.S. configurations were needed for platelets suspended in 100% plasma, triple-dose collections and random-donor platelets, creating additional cost and approval risk.
- Cerus relied heavily on third-party manufacturers, including Fresenius as the sole supplier of disposable kits. Fresenius announced workforce reductions at a facility manufacturing Cerus products, creating potential supply-chain risk.
- The company expected continuing losses and stated that it may require additional financing. Management believed available liquidity, expected debt availability and product sales would fund requirements for at least twelve months, but noted that this conclusion depended on assumptions that might prove incorrect.
- Customer and geographic concentration was material: EFS represented 25% of 2014 product revenue, and revenue from the CIS was $6.6 million. The EFS contract was scheduled to expire in November 2015.
- Other principal risks included regulatory delays, limited reimbursement, slow market adoption, competition, foreign-exchange exposure, product liability, intellectual-property claims, distributor execution and potential inventory obsolescence.
- Management concluded that internal control over financial reporting was ineffective at December 31, 2014 because of material weaknesses involving inventory valuation and cost of product revenue, and the timeliness and accuracy of accrued-liability adjustments. Ernst & Young issued an adverse opinion on internal control effectiveness, while giving an unqualified opinion on the financial statements.
Most important facts for investors to verify
- Progress toward U.S. blood-center licensing, process validation, customer implementation and actual U.S. revenue generation.
- Cash burn, remaining liquidity and whether Oxford Finance Term Loan B and Term Loan C become available under their conditions.
- Completion and results of the FDA-required platelet post-approval study and the ongoing red blood cell chronic-anemia trial.
- Resolution of the disclosed internal-control material weaknesses and any effects on future financial reporting.
- Renewal and economics of the EFS agreement, distributor transitions and customer concentration.
- Fresenius manufacturing continuity, alternative supplier qualification and the $8.5 million of 2015 minimum purchase commitments.
- Impact of the January 2015 public offering, which generated approximately $75.7 million of net proceeds from 14.6 million shares, on liquidity and dilution.